Liraglutide

Liraglutide is a glucagon-like peptide-1 receptor agonist, sometimes called an incretin mimic, and it belongs to the same broad family as later drugs such as semaglutide. It is a modified version of human GLP-1, a hormone released by the gut after eating; chemists altered the natural peptide and attached a fatty-acid chain that lets it bind to the blood protein albumin, which protects it from rapid breakdown and stretches its action to about a day. This design is what allows it to be given as a once-daily injection rather than needing constant dosing.

The drug was developed by the Danish company Novo Nordisk and first approved in the European Union in 2009 and in the United States in 2010, sold for type 2 diabetes under the brand name Victoza. In 2014 a higher-dose version was approved specifically for weight management under the name Saxenda, and its use was later extended to adolescents and to younger children. It is administered by subcutaneous injection and is a prescription medicine.

In type 2 diabetes, liraglutide lowers blood sugar and is typically added when metformin alone is not enough. Its standing grew after the large LEADER trial, which found that in people with type 2 diabetes at high cardiovascular risk, liraglutide reduced the combined rate of cardiovascular death, heart attack, and stroke compared with placebo, and lowered deaths from cardiovascular causes and from any cause ^[2]. This established it as a diabetes drug that also protects the heart.

Because GLP-1 also curbs appetite, liraglutide was studied as a treatment for obesity. In the SCALE trial, adults without diabetes who received the higher weight-management dose alongside diet and exercise lost substantially more weight than those on placebo, with many losing at least a tenth of their body weight ^[3]. This led to its approval as a chronic weight-management medicine for people with obesity or with excess weight plus a related health problem.

The most common side effects are gastrointestinal, especially nausea, vomiting, and diarrhea, which often ease as the body adjusts to a gradually increased dose. Less common but more serious concerns include inflammation of the pancreas, gallbladder problems, and low blood sugar when it is combined with other diabetes drugs. The product carries a boxed warning about thyroid C-cell tumors, which were seen in rodent studies; whether this applies to humans is not established, and it is avoided in people with a personal or family history of medullary thyroid cancer or the syndrome MEN 2. Liraglutide is available as a brand-name injection and, more recently, in generic form.

The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation, usually worst when starting or increasing the dose. It carries a boxed warning for thyroid C-cell tumors seen in rodents and is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN2. Rarer but serious risks include pancreatitis and gallbladder problems, and it can enhance hypoglycemia when combined with insulin or sulfonylureas.

Liraglutide is a peptide degraded by the same peptidases that clear native GLP-1, so it does not touch cytochrome enzymes and has no classic metabolic interactions.

The important one is pharmacodynamic. Liraglutide stimulates insulin in a glucose-dependent way and carries little hypoglycemia risk alone, but combined with insulin or a sulfonylurea it lowers glucose additively and hypoglycemia becomes common; this pairing drives most reported events.

Its second mechanism, slowed gastric emptying, is a theoretical interaction that mostly failed to appear when tested. Dedicated pharmacokinetic studies with acetaminophen, atorvastatin, griseofulvin, digoxin, lisinopril and combined oral contraceptives found no change large enough to matter. The exception is procedural rather than pharmacological: retained gastric contents under sedation or general anesthesia raise aspiration risk, and anesthetic teams now ask about GLP-1 agonist use for that reason. Oral drugs with a narrow therapeutic window remain the plausible place for the emptying effect to bite.

Checking a whole stack? Run it through interactions + stacks.

Liraglutide was developed by the Danish pharmaceutical company Novo Nordisk under the code name NN2211, engineered by attaching a fatty-acid chain to a near-copy of the natural incretin hormone GLP-1 so that it would bind albumin and last long enough for once-daily dosing. It received approval for type 2 diabetes in Europe in 2009 and in the United States in 2010 under the brand name Victoza, marking an important advance in the incretin class of glucose-lowering drugs.

Recognizing that GLP-1 receptor activation also reduces appetite, Novo Nordisk developed a higher-dose version approved in 2014 as Saxenda specifically for chronic weight management. A landmark chapter came with the LEADER cardiovascular outcomes trial, which demonstrated that liraglutide reduced major adverse cardiovascular events and cardiovascular death in high-risk patients with type 2 diabetes. These milestones established liraglutide as a foundational incretin therapy and helped pave the way for the later, even more potent GLP-1 agonists.

Liraglutide is widely respected as a pioneering GLP-1 receptor agonist that reshaped the treatment of both type 2 diabetes and obesity, and it remains a well-validated agent even as newer once-weekly drugs have arrived. Its strengths are compelling: glucose-dependent insulin secretion that carries a low risk of hypoglycemia, meaningful appetite suppression that drives weight loss, and, importantly, proven cardiovascular benefit demonstrated in the large LEADER trial.

Beyond glucose and weight, it has shown the ability to resolve the liver inflammation of non-alcoholic steatohepatitis, underscoring how broadly the incretin system reaches. It is fair to note that it requires a daily injection, that gastrointestinal side effects like nausea are common early on, and that some of its weight effect is more modest than the newest agents. Even so, liraglutide's combination of glycemic control, weight reduction, and documented heart protection has earned it a durable, foundational place in metabolic medicine.